Agitation in dementia, often linked to Alzheimer’s, affects about 45% of those with the disease. It impacts patients, caregivers, and families deeply. It can lead to needing residential care and lower quality of life.
At Liv Hospital, we see how much dementia agitation affects everyone involved. The FDA’s approval of Rexulti (brexpiprazole) brings hope. It’s a once-daily pill, with a 2 mg daily dose recommended after a gradual increase.
The FDA approved Rexulti after two Phase 3 studies showed it reduces agitation symptoms. We focus on evidence-based treatments for dementia agitation. Our goal is to provide full care to our patients.
Key Takeaways
- Rexulti (brexpiprazole) is the first FDA-approved medication for agitation associated with dementia due to Alzheimer’s disease.
- Agitation affects approximately 45% of people living with Alzheimer’s, significantly impacting quality of life.
- Rexulti is administered once daily, with a target dose of 2 mg daily.
- The approval was based on two Phase 3, randomized, double-blind, placebo-controlled studies.
- Rexulti offers a new treatment option for patients and caregivers navigating the challenges of dementia agitation.
Understanding Agitation in Alzheimer’s Disease and Dementia
It’s key to understand agitation in Alzheimer’s and dementia for better care. Agitation includes behaviors like restlessness, aggression, and shouting. It greatly affects the lives of patients and their caregivers.
Recognizing the Behavioral Signs: Pacing, Shouting, and Aggression
Agitation in Alzheimer’s shows up in many ways. You might see pacing, shouting, and aggression. These behaviors can be hard to predict and cause a lot of stress for both the patient and the caregiver.
Agitation can look different for everyone. It might include:
- Verbal aggression, such as shouting or using profanity
- Physical aggression, including hitting or shoving
- Restlessness and pacing
- Emotional lability, characterized by rapid mood swings
Why Agitation Affects 45% of Alzheimer’s Patients
About 45% of Alzheimer’s patients experience agitation. This is due to the mix of neurological, psychological, and environmental factors in the disease.
Studies show agitation is more common in advanced Alzheimer’s. This suggests a link between how severe the disease is and the presence of agitation.
| Stage of Alzheimer’s | Prevalence of Agitation |
| Mild | 20% |
| Moderate | 40% |
| Severe | 60% |
The Burden on Caregivers and Risk of Residential Placement
Agitation not only affects patients but also caregivers. Managing agitation can lead to stress, depression, and a lower quality of life for caregivers.
Agitation also increases the chance of needing a residential placement. This is because it often requires care that can’t be given at home.
We know how hard it is for caregivers. We need to support them well to manage agitation. By understanding agitation, we can improve care and life quality for Alzheimer’s patients.
Rexulti: The First FDA-Approved Drug for Agitation in Dementia
The FDA approved Rexulti in May 2023. This is a big step in treating agitation in dementia caused by Alzheimer’s. It brings hope to patients and their caregivers who have been looking for effective treatments.
The Historic May 2023 FDA Approval of Brexpiprazole
In May 2023, the U.S. Food and Drug Administration approved Rexulti (brexpiprazole). It’s for treating agitation in dementia due to Alzheimer’s. This decision was based on strong clinical trial data showing its safety and effectiveness.
The FDA’s approval of Rexulti is a historic moment. It meets a big need in treating agitation in dementia. Agitation affects about 45% of Alzheimer’s patients. Before, there were no FDA-approved treatments for this symptom.
Clinical Evidence from Phase 3 Trials Demonstrating Effectiveness
The approval of Rexulti came from two Phase 3 trials. These trials showed that Rexulti significantly reduces agitation symptoms. This evidence proves the drug’s effectiveness in managing agitation in dementia.
| Trial Characteristics | Trial 1 | Trial 2 |
| Duration | 12 weeks | 12 weeks |
| Study Design | Randomized, double-blind, placebo-controlled | Randomized, double-blind, placebo-controlled |
| Outcome | Statistically significant reduction in agitation | Statistically significant reduction in agitation |
How to Take Rexulti: Dosing, Titration, and Daily Administration
Rexulti is a once-daily oral medication. The recommended dose is 2 mg daily, reached through a titration schedule. This dosing helps minimize side effects while maximizing benefits.
The typical dosing schedule for Rexulti is as follows:
- Day 1: 0.5 mg once daily
- Days 2-4: 1 mg once daily
- Days 5-7: 2 mg once daily (target dose)
It’s important for patients and caregivers to follow the dosing schedule. They should consult their healthcare provider if they have any questions or concerns about taking Rexulti.
Conclusion
We understand the challenges of managing agitation in Alzheimer’s disease. This condition affects millions globally. The FDA’s approval of Rexulti (brexpiprazole) is a big step forward.
Rexulti is a new option for treating aggressive dementia. It has shown success in clinical trials. This means it can help reduce agitation and improve life for patients and their caregivers.
We are dedicated to top-notch healthcare, including for international patients. Rexulti is a key part of our plan to improve Alzheimer’s care. By using Rexulti, we aim to make a real difference in the lives of those affected by Alzheimer’s.
FAQ
What is the first FDA-approved medication for agitation associated with dementia due to Alzheimer’s disease?
Rexulti (brexpiprazole) is the first FDA-approved medication for this condition. It marks a significant advancement in treatment options.
How is Rexulti administered, and what is the recommended target dose?
Rexulti is given as a once-daily oral medication. The recommended target dose is 2 mg daily, with a titration schedule.
What were the results of the clinical trials that led to Rexulti’s FDA approval?
Two Phase 3 studies showed Rexulti’s effectiveness in reducing agitation symptoms. These studies support its safety and efficacy.
What are the common symptoms of agitation in Alzheimer’s disease?
Symptoms include excessive motor activity, verbal aggression, and restlessness. Pacing and emotional lability are also common. These symptoms cause distress for patients and caregivers.
How prevalent is agitation among Alzheimer’s patients?
Agitation affects about 45% of Alzheimer’s patients. It poses significant challenges for caregivers and has a big social impact.
What is the significance of Rexulti’s approval for patients and caregivers?
Rexulti’s approval is a major step forward. It addresses the complex needs of patients and caregivers, improving their quality of life.
Are there other FDA-approved treatments for agitation in dementia?
Before Rexulti, there were no FDA-approved medications for agitation in dementia due to Alzheimer’s. Rexulti is a groundbreaking treatment option.
How does Rexulti impact the quality of life for Alzheimer’s patients and their caregivers?
Rexulti reduces agitation symptoms. This can greatly improve the quality of life for Alzheimer’s patients and their caregivers, easing some of the burden and distress.
References
JAMA Network. Evidence-Based Medical Insight. Retrieved from https://jamanetwork.com/journals/jamaneurology/fullarticle/2811629
Departments
Related Videos
Our Doctors
News
